

# VERNERO MARTA

Born in Moncalieri (TO) il 21/07/1991  
Lives in Via Torino 81/A, 10026 Santena (TO)  
346 8103333  
[martavernero@gmail.com](mailto:martavernero@gmail.com)

## WORKING EXPERIENCES

### ***Gastroenterology training in school of “malattie dell’apparato digerente” (gastroenterology) of University of Pavia.***

*Resident in gastroenterology from november 2018 until today (scheduled end of the fellowship in october 2022).*

*During this period, two extra school stage:*

- *From march 2020 to July 2020 training in inpatient gastroenterology clinic of Città della Salute e della Scienza Hospital in Turin, Italy. During this period the focus was on the management of inpatient hepatotactic diseases and outpatient HBV infection diagnosis and follow up (Tutor Dr. Marzano Alfredo)*
- *From December 2020 to September 2021 training in outpatient IBD clinic of Città della Salute e della Scienza Hospital in Turin, Italy. During this period the focus was on outpatient management of inflammatory bowel disease alongside with IBD related clinical research (Tutor Dr. Astegiano Marco and Dr. Ribaldone Davide Giuseppe)*
- *From October 2020 to November 2020 and from October 2021 until now (end of the period October 2022) training in Gastroenterology unit of ASST Rhodense Hospital. During this period the focus was on upper and lower gi endoscopy and intestinal ultrasound. In addition the training is focusing on IBD outpatient clinic and IBD clinical research, including clinical trials.*

### ***Post graduate internship in IBD outpatient clinic in Città della Salute e della Scienza Hospital in Turin, Italy.***

*From january 2017 to october 2018 internship in Città della Salute e della Scienza Hospital, gastroenterology unit, IBD outpatient clinic (responsible Dr. Astegiano Marco).*

## EDUCATION

**Medicine and surgery degree with 110/110 points cum laude.**

**High school degree in “Liceo Classico Baldessano Roccati” high school in Carmagnola, Italy.**

Graduate in 2010 with 80/100 points.

## **FOREIGN LANGUAGES**

**English level B2 (First certificate in english, Cambridge, 2010 with B grade)**

## **SCIENTIFIC CONTRIBUTION**

To data author or coauthor of 29 papers on international journals indexed on pubmed/scopus. H index: 7 (scopus, 21 june 2022)

Poster presentation in ECCO, UEGW and IG-IBD congresses.

### **COMPLETE LIST OF PUBLICATIONS:**

Venero M, Ribaldone DG, Astegiano M, Pellicano R. The recipe for the perfect inflammatory bowel disease nurse in a northern Italy tertiary IBD centre: going beyond clinical care. *Minerva Gastroenterol (Torino)*. 2022 Apr 19. doi: 10.23736/S2724-5985.22.03179-5. Epub ahead of print. PMID: 35436841.

Armandi A, Rosso C, Nicolosi A, Caviglia GP, Abate ML, Olivero A, D'Amato D, Venero M, Gaggini M, Saracco GM, Ribaldone DG, Leeming DJ, Gastaldelli A, Bugianesi E. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. *J Clin Med*. 2022 Jan 27;11(3):635. doi: 10.3390/jcm11030635. PMID: 35160087; PMCID: PMC8837035.

Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. *Aliment Pharmacol Ther*. 2021 Oct 25. doi: 10.1111/apt.16663. Epub ahead of print. PMID: 34694009.

Venero M, Schiepatti A, Maimaris S, Lusetti F, Scalvini D, Megang F, Nicolardi ML, Gabrielli GM, Sprio E, Baiardi P, Biagi F. The GLU-10: a validated ten-point score to identify poorly instructed coeliac patients in need of dietary interventions. *Minerva Gastroenterol (Torino)*. 2021 Sep 22. doi: 10.23736/S2724-5985.21.03037-0. Epub ahead of print. PMID: 34547859.

Ribaldone DG, Tribocco E, Rosso C, Armandi A, Venero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. *J Clin Med*. 2021 Jul 30;10(15):3387. doi: 10.3390/jcm10153387. PMID: 34362184; PMCID: PMC8348781.

Caviglia GP, Martini G, Armandi A, Rosso C, Venero M, Bugianesi E, Astegiano M, Saracco GM, Ribaldone DG. Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. *J Clin Med*. 2021 Jul 23;10(15):3257. doi: 10.3390/jcm10153257. PMID: 34362041; PMCID: PMC8347965.

Tontini GE, Rimondi A, Venero M, Neumann H, Vecchi M, Bezzio C, Cavallaro F. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. *Therap Adv Gastroenterol*. 2021 Jun 10;14:17562848211017730. doi: 10.1177/17562848211017730. PMID: 34178115; PMCID: PMC8202249.

Schiepatti A, Maimaris S, Nicolardi ML, Alimenti E, Venero M, Costetti M, Costa S, Biagi F. Determinants and Trends of Adherence to a Gluten-Free Diet in Adult Celiac Patients on a Long-term Follow-up (2000-2020). *Clin Gastroenterol Hepatol*. 2020 Dec 15:S1542-3565(20)31672-4. doi: 10.1016/j.cgh.2020.12.015. Epub ahead of print. PMID: 33338656.

Venero M, De Blasio F, Ribaldone DG, Bugianesi E, Pellicano R, Saracco GM, Astegiano M, Caviglia GP. The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. *J Clin Med*. 2020 Dec 4;9(12):3941. doi: 10.3390/jcm9123941. PMID: 33291846; PMCID: PMC7762036.

Ribaldone DG, Venero M, Caviglia GP. Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine

to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis. *Fundam Clin Pharmacol*. 2021 Feb;35(1):141-142. doi: 10.1111/fcp.12638. Epub 2020 Dec 21. PMID: 33289917.

Ribaldone DG, Venero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept. *Rev Esp Enferm Dig*. 2021 Feb;113(2):155. doi: 10.17235/reed.2020.7253/2020. PMID: 33207912.

Venero M, Di Leo I, Givone M, Adriani A, Bergamaschi A, Fanelli M, Astegiano M. Role of Compositum Zeolite® in management of inflammatory bowel disease: a pilot study. *Minerva Gastroenterol Dietol*. 2020 Jun;66(2):113-116. doi: 10.23736/S1121-421X.20.02682-3. PMID: 32518220.

Schiepatti A, Savioli J, Venero M, Borrelli de Andreis F, Perfetti L, Meriggi A, Biagi F. Pitfalls in the Diagnosis of Coeliac Disease and Gluten-Related Disorders. *Nutrients*. 2020 Jun 7;12(6):1711. doi: 10.3390/nu12061711. PMID: 32517378; PMCID: PMC7352902.

Venero M, Ribaldone DG, Cariti C, Ribero S, Susca S, Astegiano M, Dapavo P. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. *J Dermatol*. 2020 Jun;47(6):e216-e217. doi: 10.1111/1346-8138.15283. Epub 2020 Apr 29. PMID: 32347562.

Lenti MV, Mengoli C, Venero M, Aronico N, Conti L, Borrelli de Andreis F, Cococcia S, Di Sabatino A. Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. *Front Immunol*. 2020 Mar 23;11:485. doi: 10.3389/fimmu.2020.00485. PMID: 32269571; PMCID: PMC7109446.

Ribaldone DG, Caviglia GP, Pellicano R, Venero M, Saracco GM, Morino M, Astegiano M. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. *Rev Esp Enferm Dig*. 2020 Mar;112(3):195-200. doi: 10.17235/reed.2020.6693/2019. PMID: 32054272.

Ribaldone DG, Caviglia GP, Pellicano R, Venero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. *Scand J Gastroenterol*. 2019 Nov;54(11):1339-1345. doi: 10.1080/00365521.2019.1686057.

Epub 2019 Nov 6. PMID: 31692395.

Ribaldone DG, Venero M, Parisi S, Ditto MC, Pellicano R, Morino M, Saracco GM, Fusaro E, Astegiano M. Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. *Scand J Gastroenterol*. 2019 Oct;54(10):1233-1236. doi: 10.1080/00365521.2019.1668052. Epub 2019 Sep 24. PMID: 31549896.

Venero M. Is urotensin II a new inflammatory marker of inflammatory bowel disease? *Minerva Gastroenterol Dietol*. 2019 Sep;65(3):173-174. doi: 10.23736/S1121-421X.19.02611-4. Epub 2019 Jul 24. PMID: 31347342.

Ribaldone DG, Pellicano R, Venero M, Caviglia GP, Saracco GM, Morino M, Astegiano M. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. *Scand J Gastroenterol*. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159. Epub 2019 Apr 4. PMID: 30945576.

Venero M, Boano V, Ribaldone DG, Pellicano R, Astegiano M. Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study. *Minerva Gastroenterol Dietol*. 2019 Sep;65(3):200-203. doi: 10.23736/S1121-421X.19.02572-8. Epub 2019 Mar 27. PMID: 30917629.

Ribaldone DG, Venero M, Pellicano R. Helicobacter pylori prevalence: Are the data totally reliable? *J Pediatr Surg*. 2019 Jun;54(6):1261. doi: 10.1016/j.jpedsurg.2018.12.026. Epub 2019 Feb 16. PMID: 30824241.

Venero M, Astegiano M, Ribaldone DG. New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series. *Am J Gastroenterol*. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z. PMID: 30429591.

Venero M, Ribaldone DG, Astegiano M, Pellicano R. Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience. *G Ital Dermatol Venereol*. 2020 Jun;155(3):366-367. doi: 10.23736/S0392-0488.18.06017-0. Epub 2018 Sep 20. PMID: 30249085.

Ribaldone DG, Venero M, Astegiano M, Pellicano R. How ameliorate the

adherence in patients with inflammatory bowel disease? Scand J Gastroenterol. 2018 Aug;53(8):938-939. doi: 10.1080/00365521.2018.1485731. Epub 2018 Jul 3. PMID: 29969048.

Ribaldone DG, Venero M, Saracco GM, Pellicano R, Finocchiaro F, Caviglia GP, Astegiano M. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scand J Gastroenterol. 2018 Feb;53(2):141-146. doi: 10.1080/00365521.2017.1405070. Epub 2017 Dec 11. PMID: 29228844.

Turin, 21/June/2022

*Alberto Venero*